If validated and implemented, abbreviated impactors could effectively speed up the process of screening formulations in the early development phases, prior to full resolution impactor studies being performed on the most promising candidates. In the QC environment, combined with Efficient Data Analysis (EDA), the reduced number of impactor stages required speeds up throughput and further reduces analytical error.
Better In Vitro – In Vivo Correlation (IVIVC) has long been an industry aim. This is particularly difficult in the case of inhaled and nasal products because of the complications involved in precisely correlating drug deposition behaviour with clinical efficacy, the impact of patient-to-patient variability and the complex interaction between formulation and device.
One strategy for improving the significance of cascade impaction data is to modify the test set-up in order to mimic the in vivo drug delivery process more closely.
In the case of inhaled and nasal drug delivery products, once the drug is deposited to the target site, the absorption or lung uptake, and hence the therapeutic effectiveness of the drug, depends on the active dissolving in the small amounts of aqueous fluid and lung surfactant available.